Biotech Co. Psilera Inc. Closes $2.5 Million Series A For Transdermal DMT Research

Florida-based Psilera Inc. has secured $2.5 million in funding for research, scientific and clinical personnel hiring and general working purposes.

The company issued approximately 4.3 million shares to private buyers at a cost of $0.57 per share.

Psilera has developed a patent-pending DMT transdermal patch to be assessed in a Phase 1b clinical trial with an investigational new drug (IND) filing with the FDA before the end of the year.

Earlier this year, Psilera received DEA approval to research DMT, …

Full story available on Benzinga.com

More Biotech Co. Psilera Inc. Closes $2.5 Million Series A For Transdermal DMT Research